SCHEMBL4519983

SCHEMBL4519983

CC(CCO)OCc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 2/20 0.42
SLC1A2 P43004 2/20 0.42
SLC1A1 P43005 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 1/20 0.42
TRPA1 O75762 2/20 0.42
TSHR P16473 2/20 0.41
ALDH1A1 P00352 2/20 0.41
RCE1 Q9Y256 1/20 0.41
SLC6A2 P23975 2/20 0.41
TAAR1 Q96RJ0 2/20 0.41
MAOA P21397 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
SIGMAR1 Q99720 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22092032 1.00 SLC1A3 (0.42) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL6749224 1.00 SLC1A3 (0.42) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL2300063 0.89 LTA4H (0.44) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL17019229 0.87 RRM1 (0.44) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL31645502 0.87 RRM1 (0.44) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL17006012 0.87 RRM1 (0.44) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL27129437 0.84 TSHR (0.39) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL27032261 0.84 TSHR (0.39) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL27032110 0.84 TSHR (0.39) SLC1A3SLC1A2SLC1A1MEN1CYP1A2
SCHEMBL647500 0.84 TRPA1 (0.48) SLC1A3SLC1A2SLC1A1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020058017-A1 Hair cosmetic compositions KAO CORPORATION (JP) 2002-05-16 US claimed
EP-1190696-A2 Hair cosmetic compositions and use thereof Kao Corporation (JP) 2002-03-27 EP claimed
US-20250171427-A1 THERAPEUTIC COMPOUNDS SANOFI (FR) 2025-05-29 US disclosed
WO-2025104230-A1 BENZOXAZOLES AS MODULATORS OF IL-17A SANOFI (FR) 2025-05-22 WO disclosed
WO-2025096771-A1 MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-05-08 WO disclosed
EP-3634430-B1 MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2024-08-07 EP disclosed
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS SERVIER LAB (FR) 2024-07-25 US disclosed
CN-118184532-A Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same 中外制药株式会社 2024-06-14 CN disclosed
US-20240180941-A1 ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2024-06-06 US disclosed
CN-113454058-B Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same 中外制药株式会社 2024-03-22 CN disclosed
WO-2024054955-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2024-03-14 WO disclosed
WO-2007079862-A1 NOVEL, ACYCLIC SUBSTITUTED FUROPYRIMIDINE DERIVATIVES AND USE THEREOF FOR TREATING CARDIOVASCULAR DISEASES BAYER HEALTHCARE AG (DE) 2007-07-19 WO disclosed
CN-1853603-A Stable composition for hair dye comprising a fragrance TAKASAGO PERFUMERY CO LTD (JP) 2006-11-01 CN disclosed
EP-1714637-A2 Stable composition for hair dye comprising a fragrance Takasago International Corporation (JP) 2006-10-25 EP disclosed
US-20060218730-A1 Stable composition for hair dye TAKASAGO INTERNATIONAL CORPORATION (JP) 2006-10-05 US disclosed
US-20020058017-A1 Hair cosmetic compositions KAO CORPORATION (JP) 2002-05-16 US disclosed
EP-1190696-A2 Hair cosmetic compositions and use thereof Kao Corporation (JP) 2002-03-27 EP disclosed
EP-0890355-B1 Hair treatment composition KAO CORP (JP) 2001-05-30 EP disclosed
US-6071504-A GUANIDIUM SALT, AMINO-MODIFIED POLYSILOXANE; ODORLESS, SKIN SENSITIVITY KAO CORPORATION (JP) 2000-06-06 US disclosed
EP-0890355-A1 Hair treatment composition Kao Corporation (JP) 1999-01-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246992-A1 MACROCYCLIC LRRK2 KINASE INHIBITORS LRRK2, PARK7, PINK1 SLC1A3 1871/4885SLC1A2 1782/4885SLC1A1 1976/4885
US-20240180941-A1 ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE FABP1, PYGL, LIPC SLC1A3 2178/4885SLC1A2 1783/4885SLC1A1 1953/4885
US-20250171427-A1 THERAPEUTIC COMPOUNDS IL17A, IL2, IL36G SLC1A3 4645/4885SLC1A2 4363/4885SLC1A1 4423/4885
US-20020058017-A1 Hair cosmetic compositions FHIT, MITF, HNMT SLC1A3 214/4885SLC1A2 159/4885SLC1A1 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.